Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.

Front Oncol · 2023 · PMC9998990 · PMID 36910641

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The prognosis analysis showed highly significant differences between MT and WT groups in OS and PFS outcomes.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.